CCL5 and prostate carcinoma: The cytokine C‐C motif chemokine 5 (CCL5, previously known as RANTES) is physiologically a regulator of immune cell migration and was identified as constituting a distinct chemokine release cluster in AML (Bruserud et al., 2007) and as an important drug resistance mediator in several tumor entities: In breast, ovarian, and prostate cancer, CCL5 rendered tumor cells resistant to tamoxifen, saracatinib, cisplatin, or taxanes, respectively (Fang et al., 2018; Kato et al., 2013; Pasquier et al., 2018; Xiang et al., 2019; Yi et al., 2013; Zhou et al., 2016).